FDA grants Fast-Track designation to GW's Sativex pain treatment

GW Pharmaceuticals' (GWPH) Sativex, which is used to treat pain in patients with advanced cancer, has received Fast-Track designation from the FDA.

As a cannabinoid medicine, Sativex is the only non-opioid treatment in Phase 3 development for patients who don't respond to, or experience negative side effects, with opioid medications, GW says.

Shares are +6.8%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs